Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis - PubMed
2 days ago
- #MASH with fibrosis
- #GLP-1 receptor agonists
- #meta-analysis
- GLP-1 receptor agonists (GLP-1 RAs) significantly improve MASH resolution without worsening fibrosis and fibrosis improvement without worsening MASH in patients with F2-F3 fibrosis stage.
- GLP-1 RAs also enhance cardiometabolic parameters, including aminotransferases, MRI-proton density fat fraction, HbA1c, serum lipids, blood pressure, and anthropometric measurements.
- Treatment with GLP-1 RAs is associated with higher rates of gastrointestinal adverse events but no significant increase in serious adverse events compared to placebo.
- The meta-analysis supports GLP-1 RAs as disease-modifying agents for MASH with fibrosis, highlighting their dual benefits in improving liver histology and metabolic risk factors.
- Future studies are needed to assess long-term clinical outcomes, including liver-related and all-cause morbidity and mortality, to further validate the use of GLP-1 RAs in this high-risk population.